Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘AACR 2016 Checkpoints’

AACR 2016 PostersNew Orleans – Tuesday is the last full day of the 2016 annual meeting of the American Association for Cancer Research (AACR), and the last day of our #AACR16 rolling blog posts.

What struck me at this meeting has been the explosion in cancer immunotherapy research. It’s worth remembering that where we are today is the result of pioneering work done over the last 15 years by researchers, many of whom struggled for funding and recognition as they laid the foundation for where we are today.

Tomorrow, the Vice President of the United States, Joe Biden, will fly in to address the closing plenary session of the meeting. Mr Biden’s remarks will be live streamed by AACR (link to information).

There’s a lot happening at AACR today and tomorrow; and as conference die-hards we’ll be here to the end in order to capture some really interesting data that’s on the program.

Subscribers can login to read our AACR Day 4 commentary or you can purchase access in the blue box below.

AACR16 RegistrationNew Orleans – it’s Day 3, Monday, at the 2016 annual meeting of the American Association for Cancer Research (AACR). Attending AACR for the first time can be a daunting prospect, with a full program of activities from dawn to dusk.

For those of who don’t regularly go to large medical meetings, it’s all too easy to forget the sheer scale of the event and how mach walking is involved up and down long corridors – it’s easy to clock up 15,000+ steps on your Fitbit!

Subscribers can log-in or you can purchase a subscription by clicking on the blue box below to learn more insights…

New Orleans AACR 2016New Orleans – here at the annual meeting of the American Association for Cancer Research (AACR), the emphasis has shifted from yesterday’s education program to the start of the scientific programme.

If you didn’t make it to the Cell Press/Nanostring, “What’s Next: Bit Topics in Cancer Immunology” event yesterday evening at the Bourbon Orleans hotel in the heart of the French Quarter, you missed a great unofficial AACR16 event that featured a panel of leading experts:

  • Aviv Regev, PhD (Broad Institute of MIT and Harvard)
  • Tom Gajewski, MD, PhD (University of Chicago)
  • Dan Chen, MD, PhD (Genentech)
  • Pam Sharma, MD, PhD (University of Texas MD Anderson Cancer Center)
  • Michel Sadelain, MD, PhD (Memorial Sloan Kettering Cancer Center)
  • Jerome Galon, PhD (INSERM)
  • Ira Mellman, PhD (Genentech)
  • Catherine Wu, MD (Dana Farber Cancer Institute)

Throughout the day, schedule permitting, we’ll be posting top-line commentary from the sessions we’ve been in.

You can also catch up with the commentary from the Day 1 Live Blog, which has several updates from yesterday (Link).

Subscribers can login below or you can purchase access by clicking on the blue icon.

New Orleans StreetCarNew Orleans – the annual meeting of the American Association for Cancer Research (AACR) starts in earnest today with a full program of educational sessions presented by leading experts in different fields.

There’s a lot going on at AACR, with many sessions in parallel, so always remember the “law of two feet” – if the session you are in isn’t interesting, what you expected or isn’t meeting your needs – get up and go to another one!

Starting today and through Tuesday will be posting a daily blog with commentary around the sessions we attend and the people we speak to. It won’t be real-time, but to the extent possible we’ll be providing updates during the day.

It kills us to do semi-live posts from conferences, but they’re popular with subscribers, many of whom enjoy reading top-line commentary during the meeting, then our in-depth pieces later.

If you’d like to join the club of readers who enjoy access to our content, much of which by definition is exclusive – we don’t think anybody else does what we do or talks to as many thought leaders….

The good news is that a quarterly subscription will also cover you for ASCO 2016 in Chicago.  If you’d like to support our conference coverage, you can purchase access below. Subscribers can login to read more.

Macarons in shop windowWe’re all familiar by now with the idea of checkpoints that can be inhibitory (release the brake) or stimulatory (put the foot on the gas) on the immune system.

There are multiple checkpoint modulators in development, it’s becoming a bit like buying a macaron – which flavour do you want?

As the late Holbrook Kohrt said on the Novel Targets Podcast last year:

There are two types of checkpoint inhibitors, one checkpoint inhibitor are these series of markers that each of them when you target them, they will slow down the function of that cell. Now that’s a good thing if that cell is a suppressor cell, such as a regulatory T cell. Anti-CTLA-4, ipilimumab, the first approved immunotherapeutic monoclonal antibody targets these regulatory T cells. Essentially is this concept as you said of taking off the brake .

Now if you want to press on the gas pedal, you want to find a target that is essentially that actually increases the function of a cell you want to make work better…….

…. these ideas of the different checkpoint inhibitors, essentially we should really call them, checkpoint modulation, because the checkpoints can either be gas pedals or they can be brakes.

And ultimately, it’s a question about how do you combine them in a rational way so that way you’re not either pushing the car too hard or taking the brake off at a time when the car is rolling in the wrong direction.

So essentially, you need to do checkpoint modulation in a setting where you still have the steering wheel on your car to ensure it’s directed against the right cells, otherwise you’re going to get significant toxicity.”

Which is a good introduction to Day 5 of our Road to AACR 2016 mini-series.

Over the course of 12 days in the run up to the 2016 annual meeting of the American Association for Cancer Research (AACR), we’re taking a look at some of the areas we expect to hear more about in New Orleans.

In today’s post, which continues our look at some of novel cancer immunotherapy targets, we’re look at the modulation of GITR (glucocorticoid-induced tumor necrosis factor receptor related gene) and companies that are targeting this.

GITR was named as the 12th most promising cancer immunotherapy target by the National Cancer Institute (NCI) back in 2006.  Interestingly, high GITR expression can be found on both T cells and NK cells.

There are now several agonist antibodies in development and entering the clinic that seek to activate GITR, and new data is expected at AACR 2016.

What GITR pathway data is worth looking out for at AACR 2016?

If you want to know more about why GITR matters, and where it fits into the cancer immunotherapy landscape then do read more. 

Subscribers can login or you can purchase access below.

Iwakuni Bridge

Cherry Blossoms and Iwakuni Bridge

We’re continuing our countdown to the 2016 AACR annual meeting in New Orleans with a look at anti TIM-3 and LAG-3 inhibitory checkpoints and highlighting some of the companies with noteworthy abstracts.

In case you missed it, yesterday AACR announced that Vice President Biden will be delivering remarks on the final day of the meeting, Wednesday, April 20th in the “Highlights 2016: Vision for the Future” Plenary Session. As conference diehards, we will be there in person, but AACR have announced they plan to livestream it to the world. It’s a fitting finale to what is set to be a “must attend” meeting for those with an interest in cancer new product development and in particular, cancer immunotherapy.

What can we learn from AACR abstracts on TIM–3 and LAG–3?

There is some early clinical data that we will be checking out (no pun intended) on TIM-3 and LAG-3.

Subscribers can read Day 2 of our “Road to AACR 2016” coverage by logging in, or you can purchase access below.

New Orleans Jazz

New Orleans Jazz

Most of the abstracts for the 2016 annual meeting of the American Association for Cancer Research (Twitter #AACR16) in New Orleans are now available online, which raises the intriguing question:

What are the top 10 abstracts at AACR 2016? 

If you’re a subscriber, take a moment to think which ones would be on your list, BEFORE you read this post.

Rather than give chapter and verse on a long raft of abstracts, in this second preview post I’ve chosen to focus on a few interesting, intriguing or important issues. Clearly, everyone will have their own way of defining a top 10 list, never mind choosing them! I do hope this starts a debate in your group, it’s always cool discussing science, after all.  Which ones would you choose and why?

What I wanted to do was highlight some of the critical scientific or clinical questions that I have written down in my little black book over the last year or so for which we need solid answers in order to move our understanding of the cancer research along. That list is very long and always seems to be getting longer!  The good news is that we may have answers to some of them at AACR next month. 

Here goes, in no particular order…

Subscribers can login to read more or you can purchase access below:

New Orleans riverfront streetcarThe 2016 annual meeting of the American Association for Cancer Research (AACR) takes place next month in New Orleans. (Twitter #AACR16).

While many people have focused on the presentation of clinical data at ASCO, we have long argued that emerging scientific data at AACR actually give early hint of what’s to come down the pipeline.

Anticipating these trends and spotting promising new compounds or combinations is probably more art than science, but nonetheless is a very useful and important exercise.

AACR is the most important meeting of the year for cancer new product development! 

Tomorrow, we will be reviewing the actual abstracts, posters, late breakers and what they entail, including important new data such as BMS’s CheckMate–141 exploring nivolumab in Head & Neck cancer as well as the combination of nivolumab plus ipilimumab in CheckMate–069 for advanced melanoma.

In the meantime, what are the main hot topics emerging from this year’s meeting in targeted therapies and immunotherapies?  What do the key scientific sessions tell us about new directions that lie ahead?

To learn more, subscribers can sign-in below or you sign-up in the blue box.

error: Content is protected !!